Latest Ratios: P/E Ratio 26.6x · EV/EBITDA 5.1x · ROE 23.7%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $841M | $1.8B | $1.2B | $1.3B | $785M | $767M | $704M | $688M | $566M | $559M | $378M |
| Enterprise Value | $1.5B | $2.5B | $1.9B | $1.7B | $1.3B | $839M | $797M | $540M | $431M | $441M | $229M |
| P/E Ratio → | 26.57 | 26.76 | 15.40 | 23.86 | — | 10.04 | 26.36 | — | — | — | — |
| P/S Ratio | 1.03 | 2.35 | 1.83 | 2.27 | 1.69 | 2.77 | 2.27 | 2.32 | 2.02 | 19.62 | 220.79 |
| P/B Ratio | 3.41 | 6.09 | 5.06 | 6.58 | 4.03 | 3.78 | 3.78 | 7.87 | 6.18 | 5.37 | 2.80 |
| P/FCF | 2.50 | 5.61 | 5.70 | 4.69 | 6.40 | 7.55 | — | 32.25 | 3.90 | — | — |
| P/OCF | 2.55 | 5.58 | 5.65 | 4.68 | 6.32 | 7.40 | 7.49 | 24.78 | 3.34 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.24 | 3.08 | 3.04 | 2.85 | 3.03 | 2.57 | 1.82 | 1.54 | 15.50 | 133.66 |
| EV / EBITDA | 5.07 | 6.12 | 5.74 | 5.44 | 7.66 | 9.70 | 6.76 | — | 4.77 | — | — |
| EV / EBIT | 8.18 | 14.45 | 11.28 | 10.82 | 38.42 | 47.57 | 14.11 | — | — | — | — |
| EV / FCF | — | 7.72 | 9.58 | 6.28 | 10.77 | 8.26 | — | 25.30 | 2.97 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% | 34.7% | 40.9% | 90.9% | 87.6% |
| Operating Margin | 24.0% | 24.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% | -8.0% | -7.4% | -264.9% | -5498.7% |
| Net Profit Margin | 8.1% | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.7% | 23.7% | 32.6% | 24.7% | -12.6% | 36.8% | 19.6% | -25.4% | -40.0% | -62.7% | -85.6% |
| ROA | 3.8% | 3.8% | 4.9% | 4.2% | -2.7% | 10.7% | 5.6% | -7.6% | -18.3% | -50.3% | -72.5% |
| ROIC | 14.0% | 14.0% | 15.5% | 18.4% | 5.0% | 4.8% | 38.8% | — | — | — | — |
| ROCE | 15.8% | 15.8% | 18.5% | 23.4% | 5.8% | 4.3% | 22.1% | -22.8% | -19.9% | -62.1% | -81.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 3.12 | 3.75 | 3.45 | 3.64 | 1.28 | 1.43 | 0.25 | 0.13 | 0.01 | 0.03 |
| Debt / EBITDA | 2.28 | 2.28 | 2.53 | 2.13 | 4.12 | 2.99 | 2.26 | — | 0.13 | — | — |
| Net Debt / Equity | — | 2.29 | 3.45 | 2.23 | 2.75 | 0.36 | 0.50 | -1.70 | -1.48 | -1.13 | -1.11 |
| Net Debt / EBITDA | 1.67 | 1.67 | 2.33 | 1.38 | 3.11 | 0.84 | 0.79 | — | -1.50 | — | — |
| Debt / FCF | — | 2.10 | 3.88 | 1.59 | 4.37 | 0.71 | — | -6.95 | -0.93 | — | — |
| Interest Coverage | 2.13 | 2.13 | 2.33 | 1.91 | 0.54 | 0.84 | 1.95 | -24.00 | -0.94 | — | -1000.87 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 | 1.27 | 1.27 | 4.24 | 6.92 |
| Quick Ratio | 1.48 | 1.48 | 0.88 | 1.10 | 0.86 | 1.07 | 1.10 | 1.22 | 1.23 | 4.18 | 6.86 |
| Cash Ratio | 0.92 | 0.92 | 0.32 | 0.68 | 0.40 | 0.67 | 0.73 | 0.84 | 0.78 | 3.77 | 6.68 |
| Asset Turnover | — | 0.47 | 0.38 | 0.50 | 0.40 | 0.40 | 0.48 | 0.97 | 0.96 | 0.21 | 0.01 |
| Inventory Turnover | 7.76 | 7.76 | 7.15 | 7.44 | 5.47 | 7.26 | 8.34 | 20.08 | 21.19 | 1.43 | 0.16 |
| Days Sales Outstanding | — | 98.82 | 132.10 | 115.61 | 144.07 | 139.54 | 98.10 | 89.75 | 101.46 | 127.78 | 454.17 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 6.5% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.8% | 3.7% | 6.5% | 4.2% | — | 10.0% | 3.8% | — | — | — | — |
| FCF Yield | 40.0% | 17.8% | 17.6% | 21.3% | 15.6% | 13.3% | — | 3.1% | 25.6% | — | — |
| Buyback Yield | 3.0% | 1.4% | 5.2% | 5.8% | 1.8% | 6.2% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 3.0% | 1.4% | 5.2% | 5.8% | 1.8% | 6.2% | 0.0% | 0.1% | 0.1% | 0.0% | 6.5% |
| Shares Outstanding | — | $40M | $40M | $42M | $34M | $41M | $35M | $33M | $33M | $30M | $24M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying COLL stock.
Collegium Pharmaceutical, Inc.'s current P/E ratio is 26.6x. The historical average is 20.5x. This places it at the 80th percentile of its historical range.
Collegium Pharmaceutical, Inc.'s current EV/EBITDA is 5.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.6x.
Collegium Pharmaceutical, Inc.'s return on equity (ROE) is 23.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -37.8%.
Based on historical data, Collegium Pharmaceutical, Inc. is trading at a P/E of 26.6x. This is at the 80th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Collegium Pharmaceutical, Inc. has 59.3% gross margin and 24.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Collegium Pharmaceutical, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Leverage Limits Shortfall Tolerance
Metrics are mathematically derived from official filings.
Low Headline Multiples Mask Leverage
Based on reported figures, COLL trades at a 24.81 trailing P/E and 4.88 EV/EBITDA, yet a 3.25 forward P/E implies sharp expected earnings recovery that depends on margins returning to prior levels.
The gap between the trailing P/E of 24.81 and the forward P/E of 3.25 suggests the market is pricing in a substantial earnings rebound rather than the current quarterly run-rate, which warrants scrutiny given the recent EPS miss and net margin of 8.1%. The EV/EBITDA of 4.88 is undemanding relative to specialty pharma peers such as Supernus at 5.46 and Harmony at 5.74, but the enterprise value includes roughly $1.1B of debt, so equity holders bear most of the leverage risk. Investors should monitor whether forward estimates are realized before treating the low multiples as evidence of mispricing.
Operating Margin Recovery Remains Fragile
According to reported quarterly figures, COLL's operating margin rebounded to 11.9% in 2026Q3 from 1.9% in 2026Q2, yet remains well below the 30.4% peak reported in 2025Q3.
The swing from a 1.9% operating margin to 11.9% in consecutive quarters suggests that SG&A discipline and gross margin recovery to 58.0% are driving earnings, but the trajectory is volatile rather than structurally stable. Compared with its own 2025 history, current profitability is roughly 18 percentage points weaker at the operating line, which may indicate that prior peak margins reflected favorable accrual timing. Earnings quality appears sensitive to rebate and return accruals, and further analysis of those components is warranted before extrapolating recent recovery.
Debt Service Comfort Deteriorating Sharply
Based on the reported figures, COLL's debt-to-equity ratio rose to 3.67 in 2026Q3 while interest coverage fell to 1.36, down from 3.00 in 2025Q3, suggesting narrowing debt service headroom.
Compared with its own history, the debt-to-EBITDA ratio expanded from 7.79 to 36.42 over the past year, which appears driven by compressed quarterly EBITDA rather than new borrowing alone. An interest coverage ratio near 1.4 leaves little room for earnings shortfalls before debt service becomes strained, a concern amplified by the roughly $1.1B debt load relative to equity of about $296M. Refinancing and covenant terms are not disclosed in the provided data, so the degree of near-term risk cannot be fully assessed from these figures.
Thin Current Buffer Against Obligations
As reported in financial statements, COLL's current ratio declined to 1.01 and quick ratio to 0.87 in 2026Q3, down from 1.71 and 1.62 in 2026Q1, leaving a narrow cushion against near-term liabilities.
A quick ratio below 1.0 means the company relies on cash generation and receivable collection rather than liquid assets alone to meet current obligations, which becomes a concern given cash of $144.8M against roughly $1.1B of debt. The cash conversion cycle of 219 days, driven by a DIO of 127 and DSO of 102, suggests working capital is absorbing significant capital and may tie up liquidity. Under a severe stress scenario involving a revenue shock or tightened opioid production quotas, this liquidity position would likely require reliance on operating cash flow, which the provided data does not guarantee.
Cash Generation Overstates Financial Flexibility
Based on reported figures, COLL's cumulative operating cash flow of roughly $636M over ten quarters appears strong, yet a 3.67 debt-to-equity ratio suggests cash generation may overstate true financial flexibility.
The most commonly misapplied metric for a specialty pharma company with heavy amortization is EV/EBITDA or free cash flow yield, which can flatter a leveraged business by excluding the cost of acquired intangibles and debt service obligations. Using FCF margin alone obscures that quarterly figures swing from -5.8% to 59.6% largely on working capital timing. A more appropriate lens would be net debt to normalized free cash flow after amortization and rebate accrual adjustments, which would better reflect the capacity to service roughly $1.1B of debt.